EASL Releases Updated Clinical Guidelines for Autoimmune Hepatitis in 2025
Autoimmune hepatitis, or AIH, is a chronic condition in which the immune system attacks the liver, causing ongoing inflammation that can lead to scarring, cirrhosis, and liver failure if left untreated. It affects people of all ages, with two peaks of incidence, one in childhood and adolescence and another in middle age and beyond. The condition is generally manageable with immunosuppressive medications, but it typically requires long-term treatment, and finding the right combination and dose for each individual can take time and careful monitoring.
In 2025, the European Association for the Study of the Liver, known as EASL, published its first comprehensive update to the clinical practice guidelines for managing autoimmune hepatitis since 2015. The new guidelines, led by hepatologist George N. Dalekos and published in the Journal of Hepatology, reflect a decade of research and were developed through a structured consensus process involving leading hepatologists from across Europe. They carry significant practical implications for patients receiving care at centers that follow these recommendations.
One of the most meaningful updates for patients is the formal recognition of mycophenolate mofetil, or MMF, as a first-line treatment alternative to azathioprine. Azathioprine has long been paired with corticosteroids as the standard induction regimen, but some patients cannot tolerate it due to side effects or do not respond to it adequately. The 2025 guidelines now explicitly acknowledge MMF as a comparable or potentially superior option for many adults, while cautioning that it carries teratogenic risks and should be used with particular care in patients who are pregnant or planning a pregnancy.
The standard induction approach continues to involve predniso(lo)ne at doses of 0.5 to 1 mg per kilogram daily, combined with azathioprine or mycophenolate mofetil. The guidelines now recommend evaluating a patient's response over a window of 6 to 12 months, rather than requiring a firm assessment at exactly 6 months. This change reflects real-world variability in how patients respond and gives clinicians more flexibility in adjusting treatment plans without prematurely labeling someone as a non-responder.
For long-term maintenance therapy, the guidelines recommend azathioprine or MMF as monotherapy, or in combination with a low dose of corticosteroids, adjusted to sustain a stable complete biochemical response. The updated guidelines emphasize that most patients with AIH will need long-term, often lifelong, immunosuppression, and that even patients with advanced fibrosis or compensated cirrhosis should receive treatment because controlling inflammation can slow or halt disease progression.
For patients and families managing AIH, these updated guidelines signal continued progress in standardizing care and expanding treatment options. They also reinforce the importance of specialist follow-up and individualized treatment planning, since response to therapy and tolerance of medications can vary considerably from person to person.